Invasive Aspergillosis
📧 Sign up to get email alerts when something new happens for Invasive Aspergillosis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2021-08-20EMA Expired: Caspofungin Accord (caspofungin acetate) — Accord Healthcare S.L.U.
EU assessment indicates Caspofungin Accord has expired status and is no longer active on the market.
-
CLINICAL_TRIALS withdrawal · 2017-11-01Clinical Trial Update: Drug/Drug Interactions With F901318 [Phase 1]
A Phase 1 trial assessing drug interactions with F901318 in invasive aspergillosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-11-01Clinical Trial Update: Pharmacokinetics of IV Formulation [Phase 1]
Phase 1 pharmacokinetics study of an intravenous formulation from F2G Biotech GmbH for invasive aspergillosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-09-02Clinical Trial Update: A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis [Phase 4]
This Phase 4 trial evaluating voriconazole plus micafungin versus voriconazole alone for invasive aspergillosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-05-11Clinical Trial Update: Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects [Phase 3]
A Phase 3 clinical trial evaluating a voriconazole and anidulafungin combination for invasive aspergillosis in pediatric subjects has been w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2012-04-20Clinical Trial Update: Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis [Phase 2]
A Phase 2 trial evaluating voriconazole plus micafungin versus voriconazole plus placebo for invasive aspergillosis was withdrawn.